3 results
To assess and compare efficacy (complete response [CR] rate and overall survival [OS]) between SGI-110 and TC in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
The anti-TIM-3 monoclonal antibody MBG453 is a novel immunotherapeutic agent with promising activity seen in AML and MDS. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with…
Primary Objective: Compare Atellica VTLi Sepsis biomarker values from capillary whole blood from fingerstick with anticoagulated whole blood and plasma from venipuncture.Secondary Objectives: Correlate the blood and plasma outcomes on the Atellica…